原発性胆汁性胆管炎(原発性胆汁性肝硬変)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0675
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年1月14日
◆ページ数:140
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cholangitis – Pipeline Review, H1 2020, provides an overview of the Primary Biliary Cholangitis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cholangitis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 9, 4, 1, 1 and 3 respectively.

Primary Biliary Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cholangitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Primary Biliary Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Biliary Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Biliary Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cholangitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cholangitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Biliary Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Overview
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Therapeutics Development
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Therapeutics Assessment
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Companies Involved in Therapeutics Development
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Drug Profiles
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Dormant Projects
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Discontinued Products
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Abcuro Inc, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Allergan Plc, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Cadila Healthcare Ltd, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Calliditas Therapeutics AB, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd., H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Dr. Falk Pharma GmbH, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Eli Lilly and Co, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Enanta Pharmaceuticals Inc, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Genfit SA, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by GenKyoTex SA, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Gilead Sciences Inc, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by GlaxoSmithKline Plc, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Kowa Co Ltd, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by MYR GmbH, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by NGM Biopharmaceuticals Inc, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Novartis AG, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by PRISM Pharma Co Ltd, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Tiziana Life Sciences Plc, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Virobay Inc, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects, H1 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products, H1 2020

【掲載企業】

Abcuro Inc
Allergan Plc
Cadila Healthcare Ltd
Calliditas Therapeutics AB
Chia Tai Tianqing Pharmaceutical Group Co Ltd.
Dr. Falk Pharma GmbH
Eli Lilly and Co
Enanta Pharmaceuticals Inc
Genfit SA
GenKyoTex SA
Gilead Sciences Inc
GlaxoSmithKline Plc
Kowa Co Ltd
MYR GmbH
NGM Biopharmaceuticals Inc
Novartis AG
PRISM Pharma Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Tiziana Life Sciences Plc
Virobay Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[原発性胆汁性胆管炎(原発性胆汁性肝硬変)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆